Home / Levodopa and Decarboxylase Inhibitor / Canada
CA ATC N04BA02 · updated 2 Nov 2026
Levodopa and Decarboxylase Inhibitor shortage in Canada
Is there a Levodopa and Decarboxylase Inhibitor shortage in Canada?
Yes. As of 2 Nov 2026, 6 Levodopa and Decarboxylase Inhibitor products are reported short in Canada, the first since 28 Nov 2019. The company estimate for the return is 6 Nov 2026 (latest 30 Nov 2026). Main reason: manufacturing problem.
Also short in Czechia, Norway, Sweden. All countries.
Affected products in Canada
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | TEVA-LEVOCARBIDOPA (100) | TEVA CANADA LIMITED | 28 Nov 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | TEVA-LEVOCARBIDOPA (500) | TEVA CANADA LIMITED | 4 Dec 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | TEVA-LEVOCARBIDOPA (100) | TEVA CANADA LIMITED | 20 Feb 2020 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | TEVA-LEVOCARBIDOPA (100) | TEVA CANADA LIMITED | 25 Mar 2020 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | MINT-LEVOCARB (100 count bottles) | MINT PHARMACEUTICALS INC | 8 Dec 2020 | 30 Nov 2026 | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | AA-LEVOCARB CR (100 BTL) | AA PHARMA INC | 6 Oct 2026 | 6 Nov 2026 | Manufacturing problem Disruption of the manufacture of the drug |
Source
Health Canada, Health Product Shortages Canada. Official list. Mandatory company reports since 2017: actual and anticipated shortages, plus products about to be discontinued.